0001626199-24-000074.txt : 20240510
0001626199-24-000074.hdr.sgml : 20240510
20240510192513
ACCESSION NUMBER: 0001626199-24-000074
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240508
FILED AS OF DATE: 20240510
DATE AS OF CHANGE: 20240510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DURAND REMY
CENTRAL INDEX KEY: 0001973027
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37449
FILM NUMBER: 24936551
MAIL ADDRESS:
STREET 1: C/O ALPINE IMMUNE SCIENCES, INC.
STREET 2: 185 EAST BLAINE STREET, SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98012
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC.
CENTRAL INDEX KEY: 0001626199
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 208969493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-788-4545
MAIL ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Nivalis Therapeutics, Inc.
DATE OF NAME CHANGE: 20150211
FORMER COMPANY:
FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141121
4
1
wk-form4_1715383504.xml
FORM 4
X0508
4
2024-05-08
0
0001626199
ALPINE IMMUNE SCIENCES, INC.
ALPN
0001973027
DURAND REMY
C/O ALPINE IMMUNE SCIENCES, INC.
188 EAST BLAINE STREET, SUITE 200
SEATTLE
WA
98102
0
1
0
0
Chief Business Officer
0
Common Stock
2024-05-08
4
M
0
9845
13.20
A
47949
D
Common Stock
2024-05-08
4
M
0
25000
6.51
A
72949
D
Common Stock
2024-05-08
4
M
0
12365
4.09
A
85314
D
Common Stock
2024-05-08
4
M
0
38078
3.23
A
123392
D
Common Stock
2024-05-08
4
M
0
10000
4.76
A
133392
D
Stock Option (Right to buy)
13.20
2024-05-08
4
M
0
9845
0
D
2031-01-04
Common Stock
9845
70155
D
Stock Option (Right to buy)
6.51
2024-05-08
4
M
0
25000
0
D
2029-02-05
Common Stock
25000
0
D
Stock Option (Right to buy)
4.09
2024-05-08
4
M
0
12365
0
D
2029-06-12
Common Stock
12365
2635
D
Stock Option (Right to buy)
3.23
2024-05-08
4
M
0
38078
0
D
2030-01-22
Common Stock
38078
26922
D
Stock Option (Right to buy)
4.76
2024-05-08
4
M
0
10000
0
D
2028-11-05
Common Stock
10000
0
D
Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024.
The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
One-fourth (1/4) of the shares subject to the option will vest on February 6, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
One-fourth (1/4) of the shares subject to the option will vest on May 1, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
One-fourth (1/4) of the shares subject to the option will vest on January 23, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
One-fourth (1/4) of the shares subject to the option will vest on October 8, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
/s/ James Paul Rickey, attorney-in-fact
2024-05-10